|Bid||50.25 x 1300|
|Ask||50.30 x 3100|
|Day's Range||50.16 - 50.56|
|52 Week Range||37.62 - 55.00|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||25.93|
|Forward Dividend & Yield||1.70 (3.36%)|
|Ex-Dividend Date||Apr 30, 2020|
|1y Target Est||61.38|
French drug maker Sanofi will announce the price of the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline after it has released Phase I/II results of the trials, vaccines chief Thomas Triomphe said on Thursday. The company is expected to release the results from the Phase I/II clinical trials this month. It is also developing a vaccine with U.S. biotech firm Translate Bio, with clinical human trials expected to start this month.
Moderna has emerged as a strong competitor in the race for a coronavirus vaccine. But Moderna stock remains on a wild ride in 2020 as the need for a Covid-19 vaccine grows.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)Sanofi a French société anonyme with a registered share capital of 2,517,873,886 € Registered office : 54, rue La Boétie – 75008 Paris – France Registered at the Paris Commercial and Companies Registry under number 395 030 844Date Total number of issued shares Number of real voting rights (excluding treasury shares) Theoretical number of voting rights (including treasury shares)* October 31, 2020 1,258,964,700 1,411,078,975 1,413,674,734 * Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.This information is also available on the internet website of sanofi under « Regulated Information in France »:https://www.sanofi.com/en/investors/sanofi-share-and-adrs/share-overview/shares-and-voting-rights/Investor Relations Department Europe Tel: + 33 1 53 77 45 45 US Tel: + 1 908 981 5560 e-mail: IR@sanofi.com Media Relations Department Tel: + 33 1 53 77 46 46 e-mail: MR@sanofi.com Attachment * EN_number_of_shares_and_voting_rights_October_2020